Nucleome appoints Morrow as Chief Scientific Officer
Michelle Morrow has left her position at Avacta to join Nucleome Therapeutics as Chief Scientific Officer (CSO).
Morrow joins Nucleome with two decades of experience in drug discovery and development and executing R&D strategy across biotech and large pharma.
Prior to Avacta, Michelle was SVP, Head of invoX Therapeutics Innovation, following its acquisition of F-star Therapeutics where she held positions of increasing responsibility and most recently she was SVP, Head of Research. She also held senior scientific roles at MedImmune (now Astrazeneca).
Morrow said: “I am joining Nucleome at a pivotal stage in its growth, as the company translates unique insights from the non-coding genome into a differentiated pipeline of potential new medicines for patients with inflammatory disease. Nucleome’s ability to access previously untapped biology creates a powerful opportunity to deliver first-in-class immunomodulatory therapies, and I am eager to work with the team to advance these programmes towards the clinic and ultimately bring meaningful impact to patients’ lives.”
Nucleome’s 3D genomics platform enables the identification of functional variants in the non-coding genome and the genes that they control. Its lead candidate, NTP464, is a novel monoclonal agonist antibody which offers a new principle in the treatment of inflammatory diseases and is currently progressing towards IND enabling studies.
Dr Mark Bodmer, Chief Executive Officer at Nucleome Therapeutics, added: “We warmly welcome Michelle to Nucleome. She brings a wealth of experience in advancing drug discovery candidates through the clinical pathway. Her deep expertise in immunology and bispecific antibody therapeutics will be critical as Nucleome accelerates its ambition to tackle the molecular causes of inflammatory disease.
“Michelle is recognised for translating complex scientific and development considerations into clear, actionable insights that will strengthen decision-making across our portfolio and she will be a valuable member of our leadership team.”